Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood

• Publication date

  2006-12-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/BLOOD-2006-05-026112PMID 16917004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.

  2006cited by this paper
• A Crosstalk Between Myeloma Cells and Marrow Stromal Cells Stimulates Production of DKK1 and Interleukin‐6: A Potential Role in the Development of Lytic Bone Disease and Tumor Progression in Multiple Myeloma

  2006cited by this paper
• Regulation of bone mass by Wnt signaling.

  2006cited by this paper
• Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo.

  2006cited by this paper
• Orally Bioavailable GSK‐3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo

  2006cited by this paper
• Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.

  2006cited by this paper
• A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia

  2006cited by this paper
• Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

  2006cited by this paper
• Proteasome inhibition in multiple myeloma.

  2006cited by this paper
• IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

  2005cited by this paper
• Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression*

  2005cited by this paper
• High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

  2005cited by this paper
• Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

  2005cited by this paper
• The SCID-hu myeloma model.

  2005cited by this paper
• Minireview: transcriptional regulation in development of bone.

  2005cited by this paper
• Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo.

  2005cited by this paper
• Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

  2005cited by this paper
• Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation

  2005cited by this paper
• Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

  2004cited by this paper
• New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

  2004cited by this paper
• Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.

  2004cited by this paper
• Wnt signaling in osteoblasts and bone diseases.

  2004cited by this paper
• Bone lesions in molecular subtypes of multiple myeloma.

  2004cited by this paper
• Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells.

  2004cited by this paper
• Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis.

  2004cited by this paper
• Drug therapy: Multiple myeloma

  2004cited by this paper
• Pathogenesis of myeloma bone disease.

  2004cited by this paper
• Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells

  2004cited by this paper
• Myeloma affects both the growth and function of human osteoblast-like cells

  2004cited by this paper
• New Insights in Myeloma-induced Osteolysis

  2003cited by this paper
• Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

  2003cited by this paper
• Regulation of the osteoblast‐specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways

  2003cited by this paper
• Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease

  2003cited by this paper
• E3 Ubiquitin Ligase Smurf1 Mediates Core-binding Factor α1/Runx2 Degradation and Plays A Specific Role in Osteoblast Differentiation*

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• BMP‐2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop

  2003cited by this paper
• Multiple myeloma biology: lessons from the 5TMM models

  2003cited by this paper
• Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro.

  2003cited by this paper
• Changes in Runx2/Cbfa1 Expression and Activity During Osteoblastic Differentiation of Human Bone Marrow Stromal Cells

  2003cited by this paper
• Runx2, A multifunctional transcription factor in skeletal development

  2002cited by this paper
• Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

  2002cited by this paper
• High bone density due to a mutation in LDL-receptor-related protein 5.

  2002cited by this paper
• Radionuclide imaging in the post‐genomic era

  2002cited by this paper
• Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

  2002cited by this paper
• High bone density due to a mutation in LDL-receptor-related protein 5.

  2002cited by this paper
• High Bone Resorption in Adult Aging Transgenic Mice Overexpressing Cbfa1/Runx2 in Cells of the Osteoblastic Lineage

  2002cited by this paper
• Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.

  2002cited by this paper
• Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts *

  2001cited by this paper
• Multiple myeloma

  2001cited by this paper
• Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts

  2000cited by this paper
• The Osteoblast-specific Transcription Factor Cbfa1 Contributes to the Expression of Osteoprotegerin, a Potent Inhibitor of Osteoclast Differentiation and Function*

  2000cited by this paper
• Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity

  2000cited by this paper
• Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.

  2000cited by this paper
• Cbfa1 as a regulator of osteoblast differentiation and function.

  1999cited by this paper
• Marked Osteoblastopenia and Reduced Bone Formation in a Model of Multiple Myeloma Bone Disease in Severe Combined Immunodeficiency Mice

  1999cited by this paper
• Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone‐specific alkaline phosphatase and propeptides of type I and type III procollagens

  1997cited by this paper
• Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.

  1997cited by this paper
• Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

  1997cited by this paper
• Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin.

  1995cited by this paper
• Production of fibronectin and adherence to fibronectin by human myeloma cell lines

  1994cited by this paper
• Osteoblast stimulation in multiple myeloma lacking lytic bone lesions

  1990cited by this paper
• Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.

  1989cited by this paper
• Multiple myeloma.

  1948cited by this paper
• And Growth of Myeloma Cells Il-3 Expression by Myeloma Cells Increases Both Osteoclast Formation

  year unknowncited by this paper
• The FASEB Journal express article 10.1096/fj.05-4329fje. Published online January 25, 2006. A role of TRAIL in killing osteoblasts by myeloma cells

  year unknowncited by this paper

• Models of myeloma bone disease: In vivo and in vitro approaches.

  2026cites this paper
• Lifting the Veil on Myeloma Bone Disease

  2025cites this paper
• Retrospective cohort study on alkaline phosphatase and ICU mortality rate of multiple myeloma

  2025cites this paper
• Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword

  2025cites this paper
• In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?

  2025cites this paper
• Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies.

  2025cites this paper
• High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease

  2025cites this paper
• EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction

  2025cites this paper
• Seeing beyond the surface: bone histomorphometry re-visited-implications for diagnostic pathology.

  2025cites this paper
• Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma

  2025cites this paper
• Bridging the Gap in Understanding Bone Metastasis: A Multifaceted Perspective

  2024cites this paper
• Microbiome Modulation Uncouples Efficacy and Toxicity Induced by Programmed Death-1/Programmed Death-Ligand1 Blockade

  2024cites this paper
• Cross-Roads of Thoracic and Musculoskeletal Imaging Findings in Systemic Disorders.

  2024cites this paper
• Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma

  2023cites this paper
• Discovery of imidazo[1,2-b]pyridazine-containing TAK1 kinase inhibitors with excellent activities against multiple myeloma

  2023cites this paper
• The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease

  2023influential citation
• miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance

  2023cites this paper
• Multi‐Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma

  2023cites this paper
• Weight-Based Bisphosphonate Administration for Multiple Myeloma Patients and the Risks of Skeletal Complications

  2023cites this paper
• Diagnostic value of machine learning-based computed tomography texture analysis for differentiating multiple myeloma from osteolytic metastatic bone lesions in the peripheral skeleton

  2023cites this paper
• The Role of XBP1 in bone metabolism

  2023cites this paper
• Integrated osteoimmunomodulatory strategies based on designing scaffold surface properties in bone regeneration.

  2023cites this paper
• Oscillating Fluid Flow Activated Osteocyte Lysate‐Based Hydrogel for Regulating Osteoblast/Osteoclast Homeostasis to Enhance Bone Repair

  2023cites this paper
• Study effect of traditional chemotherapy compared with the effect of combination (chemotherapeutic plus paroxetine) on cell line of multiple myeloma

  2023cites this paper
• HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies

  2023cites this paper
• Natural Killer Cells in the Malignant Niche of Multiple Myeloma

  2022cites this paper
• Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche

  2022cites this paper
• Integrative Analysis of Enrichment and Prognostic Value of Ferroptosis-related Genes and Pathways in Multiple Myeloma.

  2022cites this paper
• Bone Disease in Multiple Myeloma: Biologic and Clinical Implications

  2022cites this paper
• The Influence of Cannabinoids on Multiple Myeloma Cells: A Scoping Review

  2022cites this paper
• Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2

  2022cites this paper
• Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma

  2022cites this paper
• Alkaline Phosphatases: Biochemistry, Functions, and Measurement

  2022cites this paper
• Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease

  2022cites this paper
• m6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease

  2022cites this paper
• Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention

  2021cites this paper
• Markers of Bone Turnover in the Evaluation of Diagnosis and Prognosis of Multiple Myeloma in a Sample of Iraqi Patients

  2021cites this paper
• The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes

  2021cites this paper
• Impact of MGUS and myeloma on skeletal health

  2021cites this paper
• Role of vertebroplasty and balloon kyphoplasty in pathological fracture in myeloma: a narrative review

  2021cites this paper
• Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma

  2021cites this paper
• Suppression of Cancer-associated bone loss through dynamic mechanical loading.

  2021cites this paper
• The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression

  2021cites this paper
• Myeloma Bone Disease: A Comprehensive Review

  2021cites this paper
• Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods

  2020cites this paper
• Examining variation in skeletal tuberculosis in a late pre-contact population from the eastern mountains of Peru.

  2020cites this paper
• Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells

  2020cites this paper
• Estimation of Beta Two Microglobulins, Fetuin-A, Resistin Serum Level in Iraqi Multiple Myeloma Patients

  2020cites this paper
• Mesenchymal stem cells as carrier of the therapeutic agent in the gene therapy of blood disorders

  2020cites this paper
• Computed tomography characteristics of multiple myeloma and other osteolytic metastatic bone lesions

  2020cites this paper
• The monocyte system in haematological malignancies

  2020cites this paper
• Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications

  2020cites this paper
• Myeloma Bone Disease

  2020cites this paper
• Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid.

  2020cites this paper
• Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells

  2020cites this paper
• Biochemistry, Immunoglobulin A

  2020cites this paper
• Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma

  2020cites this paper
• Calcium and phosphorus disorders

  2020cites this paper
• Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?

  2020cites this paper
• Multiple Myeloma Associated Bone Disease

  2020cites this paper
• Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2

  2020cites this paper
• Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment.

  2020cites this paper
• Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability

  2020cites this paper
• Old and new generation proteasome inhibitors in multiple myeloma.

  2020cites this paper
• Exosome-transferred lncRNAs at the core of cancer bone lesions.

  2019cites this paper
• The Emerging Role of Osteocytes in Cancer in Bone

  2019cites this paper
• Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

  2019cites this paper
• The emerging role of exosomes in multiple myeloma.

  2019cites this paper
• Elevated serum lncRNA TUG1 levels are a potential diagnostic biomarker of multiple myeloma.

  2019cites this paper
• Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor.

  2019cites this paper
• The Value of Anti-angiogenics in Multiple Myeloma Therapy

  2019cites this paper
• Multiple Myeloma Bone Disease

  2019cites this paper
• The functional roles of exosomal long non-coding RNAs in cancer

  2019cites this paper
• Role of Osteoblasts in Cancer-Induced Bone Disease

  2019cites this paper
• Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis

  2019cites this paper
• Myeloma-derived extracellular vesicles mediate HGF/c-Met signaling in osteoblast-like cells.

  2019cites this paper
• Silencing of LncRNA-ANCR Promotes the Osteogenesis of Osteoblast Cells in Postmenopausal Osteoporosis via Targeting EZH2 and RUNX2

  2019cites this paper
• Systemic Dysfunction of Osteoblast Differentiation in Adipose-Derived Stem Cells from Patients with Multiple Myeloma

  2019cites this paper
• PET-Computed Tomography in Myeloma: Current Overview and Future Directions.

  2019cites this paper
• Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?

  2019cites this paper
• Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma

  2019cites this paper
• Mesenchymal stem cell-associated lncRNA in osteogenic differentiation.

  2019cites this paper
• Increased Osteoblastic Activity Suppressed Proliferation of Multiple Myeloma Plasma Cells

  2019cites this paper
• miR-203a-3p.1 is involved in the regulation of osteogenic differentiation by directly targeting Smad9 in MM-MSCs

  2019cites this paper
• XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression

  2018cites this paper
• Development of Novel Anti-cancer Agents with Bone Anabolic Actions

  2018cites this paper
• Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.

  2018cites this paper
• Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

  2018cites this paper
• Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease

  2018cites this paper
• Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis

  2018cites this paper
• Multiple Myeloma and Bone: The Fatal Interaction.

  2018cites this paper
• Pain management in multiple myeloma

  2018cites this paper
• De la radiographie standard à l’IRM corps entier : 30 ans de progrès en imagerie du myélome multiple

  2018cites this paper
• The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38.

  2018cites this paper
• Multiple myeloma bone lesions in skeletal remains: Report of two known cases from the 20th century CAL Milano Cemetery Skeletal Collection

  2018cites this paper
• In vitro Models of Bone Remodelling and Associated Disorders

  2018cites this paper
• HOXC10 Regulates Osteogenesis of Mesenchymal Stromal Cells Through Interaction with Its Natural Antisense Transcript lncHOXC‐AS3

  2018cites this paper
• Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy

  2018cites this paper
• A review of epidemiology and management of multiple myeloma in a resource poor country

  2018cites this paper
• Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

  2018cites this paper